SEC Tracker
Get the app

Corbus Pharmaceuticals Holdings CRBP

Corbus Pharmaceuticals reported Q3 2026 financial results and clinical updates.

Corbus Pharmaceuticals Holdings (CRBP) filed an 8-K with the SEC on Nov 10, 2026, 8:08 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Net loss of $37.8 million for Q3 2026, compared to $23.3 million in Q3 2025.
  2. CRB-913 showed 5% mean weight loss at 60 mg dose in CANYON-1 study.
  3. TEMPO-1 Phase 3 trial for OPSCC initiated in September 2026.
  4. Announced new Chief Medical Officer with extensive oncology experience.

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Corbus Pharmaceuticals Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.